Loading
Neurotransmitter Receptor Influence on Behavior / Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes · Journal article
BMJ Mental Health · August 1, 2026
A consensus or society position rather than new primary data.
This is an expert consensus report from ECNP-GALENOS defining a research agenda for anhedonia. It identifies multiple facets of anhedonia (anticipatory reward, consummatory pleasure, reward learning) and notes that prodopaminergic antidepressants produce only small improvements, suggesting mechanisms beyond dopamine. The report recommends transdiagnostic measurement tools, mechanistic biomarkers, and innovative trial designs targeting anhedonic phenotypes.
Expert consensus meeting report. Patients with anhedonia across neuropsychiatric disorders and developmental stages; focus is transdiagnostic..
Recent meta-analytical evidence indicates prodopaminergic antidepressants produce relatively small improvements in anhedonia symptoms Anhedonia comprises multiple facets: anticipatory ('wanting') and consummatory ('liking') reward processing, reward learning, and affects social, physical, and cognitive domains Mechanisms beyond dopamine likely contribute to anhedonia despite involvement of blunted phasic dopaminergic signalling in certain facets
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that anhedonia comprises multiple dissociable reward processes and that dopamine-targeting treatments alone are insufficient. This framework supports a shift toward targeted, mechanism-based interventions informed by neurobiological phenotyping rather than diagnosis alone.
An expert consensus meeting report that defines research priorities and recommendations for anhedonia assessment and treatment, rather than reporting primary empirical findings.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that anhedonia comprises multiple dissociable reward processes and that dopamine-targeting treatments alone are insufficient. This framework supports a shift toward targeted, mechanism-based interventions informed by neurobiological phenotyping rather than diagnosis alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Anhedonia, broadly defined as a reduced ability to experience interest or pleasure, represents an important transdiagnostic neuropsychiatric symptom dimension which may benefit from targeted diagnostics and treatments. Different lines of research have proposed that it comprises multiple facets, including deficits in anticipatory (‘wanting’) and consummatory (‘liking’) reward processing as well as reward learning and affects different aspects of life (eg, social, physical, cognitive). Certain facets—more specifically anticipation, motivation and reward learning—likely involve blunted phasic dopaminergic signalling. However, recent meta-analytical evidence of human depression studies indicates that prodopaminergic antidepressants produce relatively small improvements in anhedonia symptoms and suggest that mechanisms beyond dopamine likely contribute to anhedonia. This stimulated an expert meeting to review the literature and define priorities for future research in anhedonia. A central key priority is developing a translational biologically-informed nomenclature and consensus that solves the current mismatch between constructs, paradigms and measures, and mechanisms, which separates discrete reward-related processes such as effort allocation, reward learning and anticipatory interest versus consummatory pleasure. Clinical research priorities are improved multimodal measurement tools, integrating neurobiological frameworks (eg, neuroimaging, electrophysiology and liquid biomarkers capturing dopaminergic, glutamatergic, opioid and immunometabolic pathways) and transdiagnostic studies across neuropsychiatric disorders and developmental stages. Innovative trial designs that explicitly target anhedonic phenotypes as a primary outcome and test mechanism-based interventions are also needed. Translational research recommendations include back-translation strategies that begin with patient-relevant phenotypes followed by the development of comparable human and animal tasks that target reward-related processes, such as effort allocation, reward learning and anticipatory interest versus consummatory pleasure, improve cross-species behavioural paradigms and enhance methodological rigour and reproducibility. Collectively, these recommendations will help refine the conceptualisation of anhedonia and advance its role within precision psychiatry as a mechanistically grounded target across multiple disorders.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.